{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:25:59Z","timestamp":1794630359737,"version":"4.9.1"},"reference-count":16,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Plerixafor, a direct antagonist of CXCR4\/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 \u00b5g\/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of \u22652.0 \u00d7 106 CD34+ cells per kilogram recipient weight in \u22642 LP sessions. Recipients subsequently received reduced intensity (RIC; n = 33) or myeloablative (MAC; n = 30) conditioning. Sixty-three of 64 (98%) donors achieved the primary objective. The median CD34+ cell dose per kilogram recipient weight collected within 2 days was 4.7 (0.9-9.6). Plerixafor was well tolerated with only grade 1 or 2 drug-related adverse events noted. Bone pain was not observed. Plerixafor-mobilized grafts engrafted promptly. One-year progression-free and overall survivals were 53% (95% confidence interval [CI], 36% to 71%) and 63% (95% CI, 46% to 79%) for MAC and 64% (95% CI, 47% to 79%) and 70% (95% CI, 53% to 84%) for RIC recipients, respectively. Donor toxicity was reduced relative to G-CSF mobilized related donors. This is the first multicenter trial to demonstrate that, as an alternative to G-CSF, plerixafor rapidly and safely mobilizes sufficient numbers of CD34+ cells from matched sibling donors for HCT. Engraftment was prompt, and outcomes in recipients were encouraging. This trial was registered at clinicaltrials.gov as #NCT01696461.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018027599","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:45:18Z","timestamp":1553028318000},"page":"875-883","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells"],"prefix":"10.1182","volume":"3","author":[{"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre M.","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Barnes Jewish Hospital, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals, Inc, Morgantown, WV;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"McClune","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center, Fairview, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Kim","family":"Duong","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hati","family":"Kobusingye","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandi","family":"Proue","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Drexler","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Miller","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Hosoba","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN;"},{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"issue":"17","key":"2020021109191160200_B1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"2020021109191160200_B2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"2020021109191160200_B3","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","author":"Stem Cell Trialists\u2019 Collaborative Group","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020021109191160200_B4","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood-2008-08-175323","article-title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","volume":"113","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"issue":"28","key":"2020021109191160200_B5","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020021109191160200_B6","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020021109191160200_B7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2020021109191160200_B8","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood-2016-09-739722","article-title":"Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft","volume":"129","author":"Schroeder","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020021109191160200_B9","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020021109191160200_B10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020021109191160200_B11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020021109191160200_B12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbmt.2016.10.008","article-title":"Health-related quality of life among older related hematopoietic stem cell donors (&gt;60 years) is equivalent to that of younger related donors (18 to 60 years): a related donor safety study","volume":"23","author":"Switzer","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2020021109191160200_B13","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2013.54.4577","article-title":"Improved survival after transplantation of more donor plasmacytoid dendritic or na\u00efve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201","volume":"32","author":"Waller","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020021109191160200_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2451.2451","article-title":"Lymphocyte and hematopoietic stem and progenitor cell (HSPC) subsets mobilized by either plerixafor or G-GCSF: a retrospective comparison of grafts harvested in healthy allogeneic stem cell donors [abstract]","volume":"124","author":"De Greef","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2020021109191160200_B15","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.2014.60.1203","article-title":"High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning","volume":"33","author":"Reshef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1-2","key":"2020021109191160200_B16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cell.2017.11.003","article-title":"Rapid mobilization reveals a highly engraftable hematopoietic stem cell","volume":"172","author":"Hoggatt","year":"2018","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/875\/1554725\/advances027599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/875\/1554725\/advances027599.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:53:11Z","timestamp":1581432791000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/6\/875\/246716\/Plerixafor-alone-for-the-mobilization-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018027599","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]}}}